Nuveen Asset Management LLC Acquires New Stake in Septerna, Inc. (NASDAQ:SEPN)

Nuveen Asset Management LLC purchased a new stake in Septerna, Inc. (NASDAQ:SEPN - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 23,961 shares of the company's stock, valued at approximately $549,000. Nuveen Asset Management LLC owned 0.05% of Septerna at the end of the most recent quarter.

Several other large investors also recently modified their holdings of SEPN. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Septerna in the fourth quarter valued at about $278,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Septerna in the 4th quarter valued at $241,000. Janus Henderson Group PLC acquired a new position in Septerna during the fourth quarter worth about $25,111,000. Deutsche Bank AG bought a new stake in shares of Septerna during the fourth quarter worth $239,000. Finally, Deerfield Management Company L.P. Series C acquired a new stake in shares of Septerna during the 4th quarter valued at $19,736,000.

Septerna Trading Down 1.0%

NASDAQ SEPN traded down $0.10 on Monday, reaching $10.11. The company had a trading volume of 380,550 shares, compared to its average volume of 707,671. The company's fifty day moving average is $7.49 and its 200 day moving average is $12.70. Septerna, Inc. has a 52-week low of $4.17 and a 52-week high of $28.99.

Septerna (NASDAQ:SEPN - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.11). The business had revenue of $0.22 million during the quarter. On average, analysts predict that Septerna, Inc. will post -7.11 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Cantor Fitzgerald raised their target price on Septerna from $20.00 to $25.00 and gave the stock an "overweight" rating in a research report on Friday, May 16th. Wells Fargo & Company upped their price objective on shares of Septerna from $11.00 to $18.00 and gave the company an "equal weight" rating in a report on Friday, May 16th.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.